OrganiGram Holdings Inc (OGI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
OrganiGram Holdings Inc stock (OGI) is currently trading at $1.38. OrganiGram Holdings Inc PE ratio is 12.36. OrganiGram Holdings Inc PS ratio (Price-to-Sales) is 0.67. Analyst consensus price target for OGI is $8.80. WallStSmart rates OGI as Underperform.
- OGI PE ratio analysis and historical PE chart
- OGI PS ratio (Price-to-Sales) history and trend
- OGI intrinsic value — DCF, Graham Number, EPV models
- OGI stock price prediction 2025 2026 2027 2028 2029 2030
- OGI fair value vs current price
- OGI insider transactions and insider buying
- Is OGI undervalued or overvalued?
- OrganiGram Holdings Inc financial analysis — revenue, earnings, cash flow
- OGI Piotroski F-Score and Altman Z-Score
- OGI analyst price target and Smart Rating
OrganiGram Holdings Inc
📊 No data available
Try selecting a different time range
OGI Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · OrganiGram Holdings Inc (OGI)
OGI trades 75% above its Graham fair value of $0.75, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
OrganiGram Holdings Inc (OGI) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, revenue growth. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
OrganiGram Holdings Inc (OGI) Key Strengths (3)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Revenue surging 48.70% year-over-year
Supporting Valuation Data
OrganiGram Holdings Inc (OGI) Areas to Watch (5)
Losing money on operations
Very low returns on shareholder equity
Very low institutional interest at 8.87%
Micro-cap company with very limited liquidity and high volatility
Thin profit margins with limited profitability
Supporting Valuation Data
OrganiGram Holdings Inc (OGI) Detailed Analysis Report
Overall Assessment
This company scores 44/100 in our Smart Analysis, earning a D grade. Out of 8 metrics analyzed, 3 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 2.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book, Revenue Growth. Valuation metrics including Price/Sales (0.67), Price/Book (0.69) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 48.70%.
The Bear Case
The primary concerns are Operating Margin, Return on Equity, Institutional Own.. Profitability pressure is visible in Return on Equity at 4.64%, Operating Margin at -5.38%, Profit Margin at 6.49%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 4.64% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 48.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
OGI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
OGI's Price-to-Sales ratio of 0.67x sits near its historical average of 0.69x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 6% below its historical high of 0.71x set in Mar 2026, and 0% above its historical low of 0.67x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for OrganiGram Holdings Inc (OGI) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
OrganiGram Holdings Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 280M with 49% growth year-over-year. Profit margins are thin at 6.5%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Revenue growing at 49% YoY, reaching 280M. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
ROE of 4.6% suggests the company isn't efficiently converting equity into profits.
Free cash flow is -18M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Margin expansion: can OrganiGram Holdings Inc push profit margins above 15% as the business scales?
Growth sustainability: can OrganiGram Holdings Inc maintain 49%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.93, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact OrganiGram Holdings Inc.
Bottom Line
OrganiGram Holdings Inc is a high-conviction growth story with revenue accelerating at 49% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 6.5% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About OrganiGram Holdings Inc(OGI)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Organigram Holdings Inc. produces and sells cannabis and cannabis-derived products in Canada. The company is headquartered in Moncton, Canada.